Indraprastha Medical Corporation enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


2,918	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
149	4.9	61.5	61.6	52.3
2,769	—	—	—	—
−149	−4.9	−61.5	−61.6	−52.3
₹302.09	—	—	—	—

814	740	597	478	379

1.78×	—	—	—	—
9.90×	—	—	—	—
11.88×	—	—	—	—
25.69×	—	—	—	—
1,555	1,483	1,356	1,245	1,099
280	267	244	193	151
233	223	200	153	111
—	167	157	200	144
108	108	120	131	99.9
—	107	120	130	99.8
—	59.7	36.3	69.4	44.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDRAMEDCO₹318.30

Indraprastha Medical Corporation Limited

· Pharma & Health

₹ CrorePeersARTEMISMED SHALBY GKSL GPTHEALTH LOTUSEYE DRAGARWQ KMCSHIL KOVAIMcap ₹2,918 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	2,917.9
- Cash, Equiv & ST Investments	52.3	61.6	61.5	4.9	148.6
Enterprise Value	—	—	—	—	2,769.2
Net Debt (memo)	-52.3	-61.6	-61.5	-4.9	-148.6
EV per Share	—	—	—	—	302.09

Total Capital	379.5	477.8	596.7	740.4	814.4

EV/Sales	—	—	—	—	1.78
EV/EBITDA	—	—	—	—	9.90
EV/EBIT	—	—	—	—	11.88
EV/Free Cash Flow	—	—	—	—	25.69
Reference Items — Trailing FY Values
Sales	1,098.7	1,244.7	1,356.4	1,482.5	1,555.4
EBITDA	150.7	193.4	244.3	266.9	279.7
EBIT	111.4	153.3	199.9	223.3	233.1
Operating Cash Flow	144.5	200.2	156.8	167.4	—
Free Cash Flow	99.9	130.8	120.4	107.8	107.8
FCFF (free cash flow to the firm)	99.8	130.5	119.6	107.0	—
Capital Expenditure	44.6	69.4	36.3	59.7	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.